BACKGROUND: The aim of the study is to explore the diagnostic value and clinical significance of combined detection of serum markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in non-small cell lung cancer. METHODS: CYFRA21-1, SCC Ag, NSE, CEA, and ProGRP levels of 113 patients with lung cancer, 110 patients with benign lung diseases, and 90 healthy volunteers were detected by electrochemiluminescence assay. The correlations between positive expressions and clinical and pathological parameters were analyzed. The diagnostic values of CYFRA21-1, SCC, NSE, CEA, and ProGRP were evaluated by plotting ROC curves. RESULTS: The positive expression rates of CYFRA21-1, SCC Ag, NSE, CEA, and ProGRP in the lung cancer group significantly exceeded those of benign lung disease and healthy groups (p < 0.05). In the lung cancer group, CYFRA21-1, SCC Ag, NSE, CEA, and ProGRP levels significantly varied in patients with different degrees of invasion and clinical stages in the presence/absence of lymph node metastasis (p < 0.05). AUCs of diagnosis by CYFRA21-1, ProGRP, CEA, SCC Ag, and NSE were 0.737 [95% CI (0.582 - 0.893)], 0.829 [95% CI (0.742 - 0.915)], 0.848 [95% CI (0.739 - 0.956)], 0.758 [95% CI (0.642 - 0.874)], and 0.857 [95% CI (0.764 - 0.951)], respectively, with the optimal cutoff values of 11.38 µg/mL, 103.47 pg/mL, 5.78 ng/mL, 3.92 ng/mL, and 13.36 ng/mL, respectively. The combined diagnostic sensitivity and accuracy both exceeded those based on individual markers, but the combined diagnostic specificity was slightly lower than those using CYFRA21-1, SCC Ag, and ProGRP alone. CONCLUSIONS: CYFRA21-1, SCC Ag, NSE, CEA, and ProGRP levels of patients with lung cancer increased abnormally. The combined detection effectively improved diagnostic accuracy and sensitivity.
BACKGROUND: The aim of the study is to explore the diagnostic value and clinical significance of combined detection of serum markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in non-small cell lung cancer. METHODS: CYFRA21-1, SCC Ag, NSE, CEA, and ProGRP levels of 113 patients with lung cancer, 110 patients with benign lung diseases, and 90 healthy volunteers were detected by electrochemiluminescence assay. The correlations between positive expressions and clinical and pathological parameters were analyzed. The diagnostic values of CYFRA21-1, SCC, NSE, CEA, and ProGRP were evaluated by plotting ROC curves. RESULTS: The positive expression rates of CYFRA21-1, SCC Ag, NSE, CEA, and ProGRP in the lung cancer group significantly exceeded those of benign lung disease and healthy groups (p < 0.05). In the lung cancer group, CYFRA21-1, SCC Ag, NSE, CEA, and ProGRP levels significantly varied in patients with different degrees of invasion and clinical stages in the presence/absence of lymph node metastasis (p < 0.05). AUCs of diagnosis by CYFRA21-1, ProGRP, CEA, SCC Ag, and NSE were 0.737 [95% CI (0.582 - 0.893)], 0.829 [95% CI (0.742 - 0.915)], 0.848 [95% CI (0.739 - 0.956)], 0.758 [95% CI (0.642 - 0.874)], and 0.857 [95% CI (0.764 - 0.951)], respectively, with the optimal cutoff values of 11.38 µg/mL, 103.47 pg/mL, 5.78 ng/mL, 3.92 ng/mL, and 13.36 ng/mL, respectively. The combined diagnostic sensitivity and accuracy both exceeded those based on individual markers, but the combined diagnostic specificity was slightly lower than those using CYFRA21-1, SCC Ag, and ProGRP alone. CONCLUSIONS: CYFRA21-1, SCC Ag, NSE, CEA, and ProGRP levels of patients with lung cancer increased abnormally. The combined detection effectively improved diagnostic accuracy and sensitivity.